Eli Lilly and Company $LLY is Tompkins Financial Corp’s 10th Largest Position

Tompkins Financial Corp decreased its stake in Eli Lilly and Company (NYSE:LLY) by 6.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,927 shares of the company’s stock after selling 2,144 shares during the period. Eli Lilly and Company makes up 2.2% of Tompkins Financial Corp’s portfolio, making the stock its 10th biggest position. Tompkins Financial Corp’s holdings in Eli Lilly and Company were worth $24,109,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its stake in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock valued at $12,278,292,000 after purchasing an additional 14,852,076 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after purchasing an additional 81,587 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 30th. UBS Group reduced their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Guggenheim reduced their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $939.61.

Eli Lilly and Company Stock Up 0.4%

Shares of Eli Lilly and Company stock opened at $762.84 on Friday. The stock has a market capitalization of $722.00 billion, a price-to-earnings ratio of 49.86, a PEG ratio of 1.06 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $939.86. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The business’s 50 day simple moving average is $739.17 and its 200-day simple moving average is $772.98.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Insider Activity

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock worth $2,894,841 over the last 90 days. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.